Editas Medicine raises $94.4 million in year’s first IPO

Robert Weisman, The Boston Globe, 2 February, 2015 https://www.bostonglobe.com/business/2016/02/02/editas-medicine-raises-million-year-first-ipo/cnusWaNwNdlGkPsF1QAGlL/story.html

Editas Medice is the latest CRISPR startup to go public and the first IPO in 2016.  The IPO sold 5.9 million shares at $16 each, bringing in $94.4 million.  Despite the promising IPO, the future of Editas may rest in the patent dispute currently playing out over CRISPR.  Editas has licensed the technology from the Broad Institute, which is currently in a patent battle with UC-Berkley with the results from the dispute expected in 1-2 years.

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply